Innovus Pharmaceuticals Inc. (fka INNV)

[BooDog]

10-Q Our Products
We currently generate revenue from 18 products in the U.S. and six in international countries, as follows:


1. Vesele® for promoting sexual and health (U.S. and U.K.);

2.Zestra® for female arousal (U.S., U.K., Denmark, Canada, Morocco, the UAE and South Korea);

3. Zestra Glide® (U.S, Canada and the MENA countries);

4. EjectDelay® indicated for the treatment of premature ejaculation (U.S. and Canada);

5. Sensum+® to alleviate reduced penile sensitivity (U.S., U.K. and Morocco);

6. Beyond Human® Testosterone Booster;

7. Beyond Human® Ketones;

8. Beyond Human® Krill Oil;

9. Beyond Human® Omega 3 Fish Oil;

10. Beyond Human® Vision Formula;

11. Beyond Human® Blood Sugar;

12. Beyond Human® Colon Cleanse;

13. Beyond Human® Green Coffee Extract;

14. Beyond Human® Growth Agent;

15. RecalMax™ for brain health;

16. Androferti® (U.S. and Canada) for the support of overall male reproductive health and sperm quality;

17. UriVarx™ for bladder health; and

18. ProstaGorx™ for prostate health.



In addition, we currently expect to launch in the U.S. the following products in 2017, subject to the applicable regulatory approvals, if required:

1. AllerVarx™ for the management of allergy symptoms (first half of 2017);

2. FlutiCare™ for allergic rhinitis (second half of 2017);

3. Xyralid™ for the relief of the pain and symptoms caused by hemorrhoids (second half of 2017);

4. AndroVit™ for men's health (second half of 2017);

5. Urocis™ XR for urinary tract infections (second half of 2017);

6. Apeaz™ for arthritis related pain (second half of 2017);

7. ArthriVarx™ for joint health (second half of 2017); and

8. PEVarx™ for extension of sexual intercourse time (second half of 2017).


Pipeline Products



ProstaGorx™. ProstaGorx™ is a clinical strength, multi-response prostate supplement, scientifically formulated to effectively maintain good prostate health and help in preventing prostate issues in the future. We recently launched this product in May 2017.



AllerVarx™. On December 15, 2016, we entered into an exclusive license and distribution agreement with NTC S.r.l (Italy) to distribute and commercialize AllerVarx™ in the U.S. and Canada. AllerVarx™ is a proprietary modified release bilayer tablet for the management of allergy symptoms. We expect to launch this product in the first half of 2017.



FlutiCare™ (fluticasone propionate nasal spray). Innovus acquired the worldwide rights to market and sell the FlutiCare™ brand (fluticasone propionate nasal spray) and the related third-party manufacturing agreement for the manufacturing of FlutiCare™ from Novalere FP, Inc. in February 2015 (see Note 3). The Over-the-Counter (“OTC”) Abbreviated New Drug Application (“ANDA”) filed at the end of 2014 by the third-party manufacturer, who is currently selling the prescription version of the drug, with the U.S. Food and Drug Administration (“FDA”), subject to FDA approval, may allow us to market and sell FlutiCare™ OTC in the U.S. An ANDA is an application for a U.S. generic drug approval for an existing licensed medication or approved drug. A prescription ANDA (“RX ANDA”) is for a generic version of a prescription pharmaceutical and an OTC ANDA is for a generic version of an OTC pharmaceutical. Due to the delay in approval of the third-party manufacturer’s OTC ANDA by the FDA, in May 2017, we announced a commercial relationship with a different third-party manufacturer (West-Ward Pharmaceuticals International Limited or “WWPIL”) who has an FDA approved OTC ANDA for fluticasone propionate nasal spray under which they have agreed to manufacture our FlutiCare™ OTC product for sale in the U.S. (see Note 9). We expect to launch our FlutiCare™ OTC product in the U.S. in the second half of 2017.




Xyralid™. Xyralid™ is an OTC FDA monograph compliant drug containing the active drug ingredient lidocaine and indicated for the relief of the pain and symptoms caused by hemorrhoids. We expect to launch this product in the second half of 2017.



Urocis™ XR. On October 27, 2015, we entered into an exclusive distribution agreement with Laboratorios Q Pharma (Spain) to distribute and commercialize Urocis™ XR in the U.S. and Canada. Urocis™ XR is a proprietary extended release of Vaccinium Marcocarpon (cranberry) shown to provide 24-hour coverage in the body in connection with urinary tract infections in women. We expect to launch this product in the second half of 2017.



AndroVit™. On October 27, 2015, we entered into an exclusive distribution agreement with Laboratorios Q Pharma (Spain) to distribute and commercialize AndroVit™ in the U.S. and Canada. AndroVit™ is a proprietary supplement to support overall prostate and male sexual health currently marketed in Europe. AndroVit™ was specifically formulated with ingredients known to support normal prostate health and vitality and male sexual health. We expect to launch this product in the second half of 2017.



Apeaz™. We developed our proprietary product Apeaz™, which is an OTC FDA monograph compliant drug containing the active drug ingredient methyl salicylate and indicated for the minor aches and pains of muscles and joints associated with simple backaches, arthritis, strains, bruises and sprains. We expect to launch this product in the second half of 2017.



ArthriVarx™. This nutritional supplement is designed to relieve the pain associated with arthritis. We expect to launch this product in the second half of 2017.



PEVarx™. This product is designed and tested in several hundred men to extend the length of sexual intercourse. We expect to launch this product in the second half of 2017.



See PAGES 25 - 27 ALSO
https://www.sec.gov/Archives/edgar/data/1411879/000165495417004629/innv10q_mar312017.htm

CC transcript...
https://seekingalpha.com/article/4072852-innovus-pharmaceuticals-innv-bassam-damaj-q2-2017-results-earnings-call-transcript